<DOC>
	<DOCNO>NCT01526980</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare glycaemic control biphasic insulin aspart 70 + biphasic insulin aspart 30 biphasic human insulin 30 subject type 2 diabetes .</brief_summary>
	<brief_title>Glycaemic Control Biphasic Insulin Aspart 70 30 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects Type 2 diabetes Treatment BHI ( biphasic human insulin ) 30 twice daily least three month HbA1c maximum 10.0 % BMI ( Body Mass Index ) maximum 35.0 kg/m2 Able willing perform selfblood glucose monitoring ( SBGM ) The receipt investigational drug within last 30 day prior trial Total daily insulin dose minimum 2.0 U/ ( kgÂ·day ) A history drug abuse alcohol dependence within last 5 year Impaired hepatic function Impaired renal function Cardiac disease Severe , uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>